Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
1.010
-0.030 (-2.88%)
At close: Sep 17, 2025, 4:00 PM EDT
1.000
-0.010 (-0.99%)
After-hours: Sep 17, 2025, 5:05 PM EDT
Aditxt Revenue
Aditxt had revenue of $1.00K in the quarter ending June 30, 2025, a decrease of -97.73%. This brings the company's revenue in the last twelve months to $12.05K, down -96.35% year-over-year. In the year 2024, Aditxt had annual revenue of $133.99K, down -79.23%.
Revenue (ttm)
$12.05K
Revenue Growth
-96.35%
P/S Ratio
61.53
Revenue / Employee
$464
Employees
26
Market Cap
5.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 133.99K | -511.19K | -79.23% |
| Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
| Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
| Dec 31, 2021 | 105.03K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ADTX News
- 6 days ago - Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms - PRNewsWire
- 8 days ago - Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting - PRNewsWire
- 23 days ago - Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Business Wire
- 27 days ago - Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law - PRNewsWire
- 4 weeks ago - FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis - PRNewsWire
- 4 weeks ago - Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update - PRNewsWire
- 5 weeks ago - Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative - Business Wire
- 6 weeks ago - Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference - PRNewsWire